Phoslo is a pill-form medication that contains calcium acetate as its active ingredient. It is classified as a phosphate-binding agent and is generally prescribed in Hong Kong for the management of elevated blood phosphate levels, particularly in patients with chronic kidney disease (CKD) on dialysis. Calcium acetate is also a source of elemental calcium, and the product may be used under professional guidance to support overall bone health.
Calcium acetate works by binding dietary phosphate in the gastrointestinal (GI) tract. When the calcium and phosphate form an insoluble complex, the complex is excreted in the stool rather than being absorbed into the bloodstream. This reduction in phosphate absorption helps lower serum phosphate concentrations, which is crucial for patients with CKD because excess phosphate can lead to vascular calcification and bone disease.
Key points of the pharmacologic action:
Because the compound also provides elemental calcium, it contributes modestly to the body’s calcium pool, which is a building block for bone mineralization.
Approved medical uses (Hong Kong, regulated by the Department of Health):
Note: Calcium acetate is not approved as a primary treatment for osteoporosis or general osteopenia in Hong Kong; its role in bone health is considered secondary to its phosphate-binding function.
Research has explored calcium acetate as an adjunct to improve calcium balance in patients with CKD-related bone disease. While some studies suggest it may help reduce secondary hyperparathyroidism, the use for primary osteoporosis prevention remains off-label and not approved by the Hong Kong regulatory authorities. Off-label application should only occur under the direct supervision of a physician, with individualized risk-benefit assessment.
Ideal candidates
Absolute contraindications
Relative contraindications
Special populations
When specific interaction data are limited, patients should inform their healthcare provider of all prescription medicines, over-the-counter drugs, supplements, and herbal products before starting Phoslo.
This article provides educational information about Phoslo and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Calcium acetate (Phoslo) primarily acts as a phosphate binder, whereas calcium carbonate is mainly used as a calcium supplement without significant phosphate-binding activity. This makes Phoslo more suitable for patients who need to control serum phosphate, while calcium carbonate is often chosen for general calcium supplementation.
Because calcium acetate adds calcium to the gut, patients with calcium-based kidney stones should discuss the risk with their physician. In some cases, alternative phosphate binders that do not contain calcium may be preferred.
Serum phosphate usually begins to decline within a few days of consistent dosing with meals, but the full therapeutic effect may take several weeks as diet and dialysis parameters are adjusted.
Aluminum-containing antacids can interfere with the phosphate-binding capacity of calcium acetate. If antacid therapy is needed, a non-aluminum formulation (e.g., magnesium-based) should be considered after consulting a pharmacist.
Dairy products provide additional calcium, which could raise the risk of hypercalcemia when combined with calcium acetate. Moderation and individualized dietary counseling are recommended.
Yes, but vitamin D enhances calcium absorption and may increase the chance of hypercalcemia. Your doctor may adjust the calcium acetate dose or monitor serum calcium more closely.
Take the missed pill with the next main meal you consume. Do not double the dose, and keep the medication in a cool, dry place during travel.
Coverage varies by individual insurance plans and prescription status. Patients should verify benefits with their insurer or the Hospital Authority.
Sevelamer is a non-calcium phosphate binder that does not increase calcium load, making it a preferred option for patients at high risk of hypercalcemia. Phoslo provides the added benefit of calcium supplementation but requires careful monitoring of calcium levels.
Crushing the tablet may reduce its ability to bind phosphate effectively and is not recommended. If swallowing is difficult, discuss alternative formulations with a pharmacist.
